VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE AMEX: CVM) announced today that the State of Israel’s Ministry of Health has given approval to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Israel. Israel is one of nine countries to participate in this global Phase III trial. The Phase III trial will be conducted in approximately 48 clinical centers. CEL-SCI's partner Teva Pharmaceutical Industries will be conducting the trial at three clinical centers in Israel. The Phase III trial started in the United States in late December 2010 and is expected to commence in other countries around the world within the next 30-60 days. Multikine is the Company’s flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.
